Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Rises By 16.1%

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 5,110,000 shares, a growth of 16.1% from the September 30th total of 4,400,000 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is currently 4.6 days. Currently, 7.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Citigroup dropped their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a "sell" rating on the stock in a research note on Tuesday, October 1st. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. JMP Securities reduced their price target on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating on the stock in a research note on Tuesday, July 30th. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Finally, Morgan Stanley boosted their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a research report on Monday, July 15th. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $26.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IART. Diversified Trust Co boosted its stake in Integra LifeSciences by 37.3% in the first quarter. Diversified Trust Co now owns 22,846 shares of the life sciences company's stock valued at $810,000 after acquiring an additional 6,208 shares during the period. State of Michigan Retirement System boosted its position in Integra LifeSciences by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company's stock valued at $592,000 after purchasing an additional 400 shares during the period. Olstein Capital Management L.P. grew its stake in Integra LifeSciences by 35.1% during the 1st quarter. Olstein Capital Management L.P. now owns 100,000 shares of the life sciences company's stock worth $3,545,000 after buying an additional 26,000 shares during the last quarter. Valley National Advisers Inc. acquired a new stake in Integra LifeSciences in the first quarter worth $63,000. Finally, Leeward Investments LLC MA increased its position in Integra LifeSciences by 17.8% in the first quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company's stock worth $16,039,000 after buying an additional 68,247 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 0.9 %

NASDAQ IART traded up $0.18 on Tuesday, hitting $19.50. 360,893 shares of the stock traded hands, compared to its average volume of 1,084,577. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock has a 50-day moving average of $18.72 and a 200 day moving average of $24.73. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a market capitalization of $1.54 billion, a P/E ratio of 39.00, a price-to-earnings-growth ratio of 0.65 and a beta of 1.09.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.01. The firm had revenue of $418.20 million for the quarter, compared to analysts' expectations of $413.07 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the business posted $0.71 earnings per share. As a group, analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.